Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Epstein-Barr Virus Infections 6Sarcoma, Kaposi 4Lymphoproliferative Disorders 4Nasopharyngeal Carcinoma 3Glioblastoma 3Cytomegalovirus Infections 3Multi-centric Castleman's Disease 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Acquired Immunodeficiency Syndrome 2Stomach Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Neoplasms 1Neoplasm Metastasis 1Multiple Acyl Coenzyme A Dehydrogenase Deficiency 1Macular dystrophy, corneal type 1 1Lymphoma, Extranodal NK-T-Cell 1Lymphadenopathy 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Hodgkin Disease 1Herpes Simplex 1Head and Neck Neoplasms 1HIV Infections 1Fatigue Syndrome, Chronic 1Fatigue 1EBV Lymphomas 1

Interventions

Valganciclovir 3Valacyclovir 2Polymerase Chain Reaction 2Flow Cytometry 2Cell Count 2Blood Specimen Collection 2letermovir 1dolutegravir 1Zidovudine 1VCL-CB01 vaccine 1Stem Cell Transplantation 1Specimen Handling 1Ritonavir 1Peripheral Blood Stem Cell Transplantation 1Nucleosides 1Immunologic Techniques 1Ganciclovir 1Darunavir 1Acyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Cytomegalovirus Infections × Valganciclovir × Clear all
NCT07294547 2025-12-19

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

National Taiwan University Hospital

Phase NA Recruiting
80 enrolled

Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT01972035 2022-04-12

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

University of Minnesota

Phase 2 Completed
137 enrolled 8 charts

Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT00400322 2021-03-01

Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

Karolinska Institutet

Phase NA Completed
42 enrolled
CNS

Cytomegalovirus Infections, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡